Sharon Benzeno
Known title: Chief Business Development OffCIK: 0001780854
Associated companies
Transaction History
| ADPT | ▲ Buy | Option Exercise | 24,944 | $100K | 6/29/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 1,837 | $22K | 6/29/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 24,944 | $211K | 6/29/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 51,570 | $419K | 6/29/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 154,768 | $3.3M | 6/29/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 11,034 | $134K | 6/26/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 11,034 | $232K | 6/26/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 63,103 | $831K | 3/11/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 39,063 | $0 | 3/4/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 4,290 | $52K | 12/4/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 4,157 | $35K | 12/4/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 4,157 | $17K | 12/4/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 12,604 | $212K | 12/4/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 834 | $5K | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 20,834 | $136K | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 49,480 | $324K | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 34,375 | $250K | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 119,809 | $1.5M | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 83,145 | $332K | 11/21/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 308,477 | $5.2M | 11/21/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 133,032 | $1.1M | 11/20/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 68,961 | $837K | 11/20/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 297,925 | $4.9M | 11/20/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 41,600 | $290K | 3/5/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,065 | $21K | 3/5/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 109,973 | $0 | 3/4/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,746 | $37K | 3/5/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 18,644 | $64K | 3/5/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 132,979 | $0 | 3/4/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 132,979 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 11,749 | $101K | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,670 | $32K | 3/7/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 82,372 | $0 | 3/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.